CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Onyx Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Onyx Pharmaceuticals, Inc.
249 E. Grand Avenue
Phone: (650) 266-0000p:650 266-0000 South San Francisco, CA  94080  United States Fax: (650) 266-0100f:650 266-0100
This company was Merged or Acquired on 10/1/2013.
This company ceased filing statements with the SEC on 10/11/2013.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. In its kinase inhibitor franchise, its product, Nexavar (sorafenib) tablets is approved for unresectable liver cancer and advanced kidney cancer. unresectable liver cancer and advanced kidney cancer. With its development and marketing partner Bayer HealthCare Pharmaceuticals Inc., or Bayer, the Company shares equally in the profits and losses of Nexavar worldwide except Japan. A kinase inhibitor, regorafenib, is an investigational agent that has already demonstrated positive Phase 3 survival data in metastatic colorectal cancer, and is being evaluated in a Phase 3 study in gastrointestinal stromal tumors (GIST).
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201312/31/2012YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8733 Noncommercial research organizations
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer N. AnthonyColes 52 12/17/2012 3/31/2008
Chief Financial Officer, Executive Vice President Matthew K.Fust 48 1/5/2009 1/5/2009
Executive Vice President, General Counsel, Corporate Secretary Suzanne M.Shema 55 1/1/2012 8/1/2009
10 additional Officers and Directors records available in full report.

Business Names
Business Name
Onyx Pharmaceuticals
Onyx Pharmaceuticals (Luxembourg) S.à.r.l
Onyx Pharmaceuticals (UK) Limited
5 additional Business Names available in full report.

General Information
Number of Employees: 741 (As of 12/31/2012)
Outstanding Shares: 73,338,780 (As of 8/5/2013)
Shareholders: 124
Stock Exchange: NASD
Federal Tax Id: 943154463
Fax Number: (650) 266-0100
Email Address: ir@onyx-pharm.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023